- Home
- AQN vs RARE Comparison
AQN vs RARE Comparison
Compare AQN & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQN
- RARE
- Stock Information
- Founded
- AQN 1988
- RARE 2010
- Country
- AQN Canada
- RARE United States
- Employees
- AQN N/A
- RARE N/A
- Industry
- AQN Electric Utilities: Central
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- AQN Utilities
- RARE Health Care
- Exchange
- AQN Nasdaq
- RARE Nasdaq
- Market Cap
- AQN 3.7B
- RARE 3.6B
- IPO Year
- AQN 1998
- RARE 2014
- Fundamental
- Price
- AQN $4.86
- RARE $32.25
- Analyst Decision
- AQN Hold
- RARE Strong Buy
- Analyst Count
- AQN 6
- RARE 15
- Target Price
- AQN $5.83
- RARE $95.93
- AVG Volume (30 Days)
- AQN 11.2M
- RARE 674.4K
- Earning Date
- AQN 03-07-2025
- RARE 05-01-2025
- Dividend Yield
- AQN 5.09%
- RARE N/A
- EPS Growth
- AQN N/A
- RARE N/A
- EPS
- AQN N/A
- RARE N/A
- Revenue
- AQN $2,319,538,000.00
- RARE $560,230,000.00
- Revenue This Year
- AQN $9.59
- RARE $19.40
- Revenue Next Year
- AQN $3.86
- RARE $29.92
- P/E Ratio
- AQN N/A
- RARE N/A
- Revenue Growth
- AQN N/A
- RARE 29.01
- 52 Week Low
- AQN $4.19
- RARE $33.53
- 52 Week High
- AQN $6.79
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- AQN 46.91
- RARE 31.75
- Support Level
- AQN $5.06
- RARE $33.53
- Resistance Level
- AQN $5.34
- RARE $35.47
- Average True Range (ATR)
- AQN 0.10
- RARE 1.37
- MACD
- AQN -0.02
- RARE -0.37
- Stochastic Oscillator
- AQN 8.54
- RARE 4.72
About AQN Algonquin Power & Utilities Corp.
Algonquin Power & Utilities Corp is a Canada-based diversified international generation, transmission, and distribution company. The company's operations are organized across two business units consisting of the Regulated Services Group, which owns and operates a portfolio of regulated electric, water distribution and wastewater collection, and natural gas utility systems and transmission operations in the United States, Canada, Bermuda, and Chile; and the Hydro Group, which consists of hydroelectric-generating facilities located in Canada. It generates the majority of its revenue from the Regulated Services Group segment.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.